Charles Montano, MD
Internal Medicine · Cromwell, CTNPI 1487673208
Payments from drug & device makers
Across 2,634 payments — averaging $1068.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$416K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$305K
- Supernus Pharmaceuticals, Inc.$287K
- Eli Lilly$286K
- Boehringer Ingelheim International GmbH$264K
- Sage Therapeutics, LLC$252K
- plus $1M from 54 others
Across 50 payments — averaging $2635.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$48K
- Arbor Pharmaceuticals, Inc.$33K
- Eli Lilly$24K
- Purdue Pharma L.p.$22K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- AbbVie$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$253,18726%
- Speaking & faculty fees$578,98660%
- Travel & lodging$96,48910%
- Food & beverage$38,9624%
- Education$2,3640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,815,413 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $109,726 |
| MounjaroTirzepatide | 88 | $101,655 |
| AuvelityDextromethorphan Hbr/Bupropion | 47 | $59,565 |
| FarxigaDapagliflozin Propanediol | 24 | $37,058 |
| VraylarCariprazine Hcl | 23 | $34,276 |
| RexultiBrexpiprazole | 18 | $33,593 |
| GimotiMetoclopramide Hcl | 12 | $25,311 |
| Repatha SureclickEvolocumab | 27 | $23,958 |
| EliquisApixaban | 23 | $21,417 |
| VascepaIcosapent Ethyl | 36 | $20,927 |
| Nurtec OdtRimegepant Sulfate | 17 | $19,409 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $14,385 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,253 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $9,430 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,312 | $109,72673 claims |
| Lilly USA, LLCMounjaro | $2,191 | $101,65588 claims |
| Axsome Therapeutics, Inc.Auvelity | $169,274 | $59,56547 claims |
| AstraZenecaFarxiga, Symbicort | $1,596 | $41,53135 claims |
| PfizerEliquis, Nurtec Odt | $81,478 | $40,82640 claims |
| AbbVieVraylar, Synthroid, Armour Thyroid | $416,433 | $36,71549 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $64,494 | $33,59318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $36,797 | $27,63857 claims |
| Evoke Pharma, Inc.Gimoti | $10,684 | $25,31112 claims |
| MerckJanumet | $101 | $9,43011 claims |
| Boehringer IngelheimSpiriva Respimat | $60,727 | $6,50212 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $7,051 | $5,36611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Cromwell
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
- Michael SchilskyNew Haven$601K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.